Micardis leads the charge for Boehringer Ingelheim in Japan
This article was originally published in Scrip
Executive Summary
Prescription sales at Nippon Boehringer Ingelheim (NBI) in Japan rose by around 6% to ¥173.8 billion ($1.85 billion) at reimbursement prices in calendar 2009, driven by global strategic products including Micardis (telmisartan) and Spiriva (tiotropium).